---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054868"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:55:06.433562+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics Appoints Dr. Jay Skyler to Board of Directors

## Summary
- Dr. Jay Skyler appointed as Class I director, effective May 3, 2024, to serve until 2025 annual meeting.
- Skyler is Professor of Medicine at University of Miami, former President of American Diabetes Association, and served on boards of DexCom, Amylin, and MiniMed.
- His appointment brings deep Type 1 diabetes expertise to SAB's board, supporting SAB-142 immunotherapy program.
- No material transaction or family relationship with any director or officer; compensation consistent with non-employee directors.

## SEC filing metadata
- accession: 0000950170-24-054868
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024054868/0000950170-24-054868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024054868/sabs-20240503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054868
- JSON: https://secwatch.observer/filing/0000950170-24-054868.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054868.txt

## Key facts
- Executive change
  Dr. Jay S. Skyler was appointed as Class I director at SAB Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024054868/0000950170-24-054868-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.